Tectonic Therapeutic Q3 loss widens on higher expenses

Overview

• US biotech firm's Q3 net loss widened yr/yr as R&D and admin expenses increased

• Company ended Q3 with $234.7 mln in cash, expects runway into Q1 2029

• Favorable Phase 1a safety results for TX2100 and FDA Fast Track designation announced

Outlook

• Company expects cash runway into Q1 2029 based on current operating assumptions

• Topline results from TX45 APEX Phase 2 trial in PH-HFpEF expected by end of Jan 2027

• Interim topline results from TX2100 TERRA Phase 1b trial expected by year-end 2027

Result Drivers

• R&D SPENDING - Higher research and development expenses driven by increased headcount and stock-based compensation to support pipeline programs

• ADMINISTRATIVE COSTS - General and administrative expenses rose due to higher employee-related and stock-based compensation costs

• CASH INFLOW - Net proceeds from at-the-market offering contributed to cash and cash equivalents

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Tectonic Therapeutic, Inc. is $76.00, about 274.4% above its November 4 closing price of $20.30

Reuters Recommended Reads

• Nov 5 - Fate Therapeutics Q3 net loss narrows as expenses fall

• Nov 5 - Entrada Therapeutics Q3 net loss narrows as expenses fall

• Nov 5 - Dyne Therapeutics Q3 net loss widens on higher trial costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)